25.14
Agonisti del recettore glucagone-simile
Le incretine includono il peptide-1 glucagone-simile (GLP-1) e il polipeptide insulinotropico glucosio-dipendente (GIP), che stimolano la secrezione d…
L'assunzione orale di glucosio innesca ormoni intestinali come GLP-1 e GIP chiamati incretine, che stimolano la secrezione di insulina.
Sia i GLP che il glucagone hanno origine dal preproglucagone. Il proglucagone viene trasformato in un grande peptide che include il glucagone o GLP-1 e GLP-2, dalle cellule L intestinali e da specifici neuroni del rombencefalo.
Tuttavia, il GLP-1 viene degradato dalla DPP-4 e dalle endopeptidasi ed escreto per via renale, il che lo rende terapeuticamente inadatto.
Per aggirare questo problema, sono stati sviluppati analoghi del GLP-1 metabolicamente stabili, tra cui dulaglutide, liraglutide e lixisenatide.
Questi farmaci aiutano a migliorare il controllo glicemico nei pazienti con diabete di tipo 2, da soli o in combinazione con altri farmaci. Inoltre, inducono la perdita di peso e vengono somministrati quotidianamente o settimanalmente in forma a rilascio prolungato.
Exenatide è una variante sintetica del peptide exendin-4. È un analogo del GLP-1 ma non viene metabolizzato da DPP-4, estendendone l'azione.
Un altro approccio prevede l'utilizzo degli inibitori della DPP-4 che massimizzano l'efficacia terapeutica delle incretine.
View the full transcript and gain access to JoVE Core videos
Q1: What are incretins and how do they affect insulin secretion?
Incretins are gut hormones including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) released after oral glucose intake. They stimulate insulin secretion and are responsible for 50-70% of the postprandial insulin response. Both originate from preproglucagon and preproGIP respectively, processed by intestinal L cells and hindbrain neurons to regulate glucose homeostasis.
Q2: Why is native GLP-1 unsuitable as a therapeutic drug?
Native GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) and endopeptidases, then excreted renally, resulting in a short half-life of only 1-2 minutes. This rapid inactivation prevents therapeutic efficacy when administered systemically, necessitating alternative drug strategies to exploit GLP-1's beneficial effects on glucose control.
Q3: How do GLP-1 receptor agonists like liraglutide and dulaglutide work?
GLP-1 receptor agonists are metabolically stable analogs resistant to DPP-4 degradation and renal clearance. Drugs like liraglutide (Victoza) and dulaglutide (Trulicity) bind GLP-1 receptors to stimulate insulin secretion, inhibit glucagon release, slow gastric emptying, and reduce food intake. They improve glycemic control in type 2 diabetes and induce weight loss when administered daily or weekly.
Q4: What is exenatide and how does it differ from native GLP-1?
Exenatide (Byetta) is a synthetic exendin-4 peptide variant that shares physiological properties with GLP-1 but resists DPP-4 metabolism, extending its therapeutic action. Unlike native GLP-1, exenatide maintains effectiveness long enough for clinical use. It is administered alone or combined with other drugs to manage type 2 diabetes in patients failing to meet glycemic targets.
Q5: What are DPP-4 inhibitors and how do they enhance GLP-1 efficacy?
DPP-4 inhibitors are small-molecule drugs including sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus) that block the enzyme degrading GLP-1 and GIP. By preventing enzymatic inactivation, these inhibitors extend the action of endogenously released incretins, maximizing their therapeutic efficacy without requiring exogenous peptide administration.
Q6: What metabolic effects does GLP-1 therapy produce beyond glucose control?
GLP-1 therapy suppresses glucagon secretion, delays gastric emptying, inhibits feeding behavior, and reduces hunger sensation in type 2 diabetes patients. These effects contribute to weight loss and improved metabolic outcomes. The exact mechanism underlying reduced hunger remains unclear, but GLP-1 receptor activation in the hypothalamus and other brain regions likely plays a role.
Q7: How are GLP-1 agonists administered and what are their clinical advantages?
GLP-1 agonists are administered as daily or weekly extended-release injections, improving patient compliance compared to multiple daily doses. They effectively lower blood glucose, induce weight loss, and can be used alone or combined with other diabetes medications. Their flexible dosing regimens and dual metabolic benefits make them valuable options for managing type 2 diabetes.